Register for streaming realtime charts, analysis tools, and prices.
Period:
Draw Mode:
| Volume | 542 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Moderna Inc | MRNA | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 106.18 | 05:39:56 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 106.18 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 52 | 542 | - | 62.55 - 142.79 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 05:28:56 | 1 | $ 106.22 | USD |
Moderna (MRNA) Options Flow Summary
Moderna Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 40.57B | 382.07M | - | 6.85B | -4.71B | -12.34 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Moderna News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical MRNA Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 102.37 | 111.29 | 99.30 | 105.84 | 2,880,696 | 3.81 | 3.72% |
| 1 Month | 106.40 | 115.89 | 97.00 | 105.65 | 3,054,556 | -0.22 | -0.21% |
| 3 Months | 97.39 | 115.89 | 84.06 | 100.65 | 3,819,698 | 8.79 | 9.03% |
| 6 Months | 76.73 | 115.97 | 62.55 | 93.71 | 4,427,572 | 29.45 | 38.38% |
| 1 Year | 134.67 | 142.79 | 62.55 | 102.53 | 4,043,597 | -28.49 | -21.16% |
| 3 Years | 171.79 | 497.17 | 62.55 | 219.63 | 6,998,869 | -65.61 | -38.19% |
| 5 Years | 25.83 | 497.17 | 11.54 | 147.51 | 8,829,842 | 80.35 | 311.07% |
Moderna Description
| Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 44 mRNA development programs as of early 2022, with 25 of these in clinical trials. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases. |
